While there were some overlapping DEMHCPs in common between treatments, especially when comparing reovirus and isotype control antibody or anti-PD-1 antibody combination therapy (henceforth referred to as REO + ISO or REO + ICB, respectively), we focused on DEMHCPs that are unique to each treatment considering our interest in cancer immunoediting (Fig. 4, C and D). This evidence concerns the gene PDCD1 and cancer.